TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8983399
Drug: Epristeride 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epristeride 5 mg oral dose
Study: 8983399
Drug: Epristeride 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epristeride 4.5 mg intravenous infusion
Study: 8983399
Drug: Epristeride 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epristeride 5 mg oral dose and 4.5 mg intravenous infusion
Study: 1750594
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (double-blind, placebo-controlled)
Study: 1750594
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (open administration)
Study: 6174719
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron therapy for 6 to 8 days
Study: 31402114
Drug: Guselkumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab (100 mg at weeks 0 and 4 then every 8 weeks)
Study: 31402114
Drug: Secukinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (300 mg at weeks 0, 1, 2, 3, and 4, then every 4 weeks)
Study: 28674348
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 mg) in EAC group
Study: 28674348
Drug: Rabeprazole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (10 mg) in RAC group
Study: 24977401
Drug: Sublingual alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual alprazolam (0.5 mg)
Study: 24977401
Drug: Oral alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alprazolam (0.5 mg)
Study: 22545364
Drug: Triamcinolone ointment
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone ointment (twice a day)
Study: 22545364
Drug: Oral atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atorvastatin (20 mg daily)
Study: 22545364
Drug: Placebo atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo atorvastatin tablet (daily)
Study: 22545364
Drug: Placebo triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo triamcinolone ointment (twice a day)
Study: 21535498
Drug: White Bread
Normalized name: White bread
Approvals — FDA: no, EMA: no, PMDA: no
Description: White Bread (WB) 57 g, 160 cal, 1 g fiber
Study: 21535498
Drug: Raw Cranberries
Normalized name: raw sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raw Cranberries (RC) 55 g, 21 cal, 1 g fiber
Study: 21535498
Drug: Sweetened Dried
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetened Dried Cranberries (SDC) 40 g, 138 cal, 2.1 g fiber
Study: 21535498
Drug: Sweetened Dried
Normalized name: peptone,dried
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sweetened Dried Cranberries with Less Sugar (SDC‐LS) 40 g, 113 cal, 1.8 g fiber + 10 g polydextrose
Study: 16051497
Drug: Controlled doses
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled doses of computer work involving prolonged static posture
Study: 16051497
Drug: Controlled doses
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled doses of computer work involving increased typing speed
Study: 16051497
Drug: Controlled doses
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled doses of computer work involving increased typing force
Study: 10076111
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of normal saline solution
Study: 2864073
Drug: Celiprolol (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (0.15 mg/kg/5 min iv)
Study: 2864073
Drug: Celiprolol (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (0.3 mg/kg/5 min iv)
Study: 2864073
Drug: Propranolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.1 mg/kg/5 min)
Study: 29384903
Drug: linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: linezolid 600 mg twice daily for 10 days
Study: 31391682
Drug: Chlorophytum borivilianum
Normalized name: CHLOROPHYTUM BORIVILIANUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorophytum borivilianum (CB) 3 g/day
Study: 26965722
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block (group E&G) with continuous epidural and general anaesthesia, using ropivacaine for intraoperative and postoperative blocks.
Study: 26965722
Drug: General anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia only (group G) with remifentanil for analgesia.
Study: 23673093
Drug: Compliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance with blood cultures before antibiotics protocol
Study: 17175635
Drug: Arginine treatment
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine treatment (0.4 g x kg(-1) x d(-1) orally for 7 days)
Study: 17175635
Drug: Arginine treatment
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine treatment and Placebo
Study: 10219183
Drug: Preventive oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive oral protocol consisting of elimination of bacterial plaque, mouthwash with chlorhexidine 0.12%, topical application of iodopovidone, and nystatin 500,000 units.
Study: 10219183
Drug: Palliative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative treatment for complications (Group I).
Study: 3359824
Drug: Bronchoalveolar lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoalveolar lavage with 200 ml of 25 degrees C normal saline solution
Study: 3359824
Drug: Bronchoalveolar lavage
Normalized name: lovage oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchoalveolar lavage with 200 ml of 37 degrees C normal saline solution
Study: 29200983
Drug: PROHIGH (2.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROHIGH (2.9 g.kg‐1.d‐1)
Study: 29200983
Drug: PROMOD (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROMOD (1.8 g.kg‐1.d‐1)
Study: 25689594
Drug: PPV/CI guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV/CI guided group (target PPV <12%, CI >2.5 L/min/m², MAP >70 mmHg)
Study: 23517178
Drug: Betahistine (48
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine (48 mg)
Study: 20627917
Drug: Laboratory APAP
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laboratory APAP titration
Study: 20627917
Drug: Home APAP
Normalized name: ACETAMINOPHEN 325 mg ORAL TABLET, COATED [Medique at Home APAP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home APAP titration
Study: 19108595
Drug: Moderate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate and deep sedation (MAC) using ketamine-midazolam-propofol anesthetic combination
Study: 16618562
Drug: Tolterodine extended
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine extended release (TER) 4 mg once daily 4 hours or less before bed
Study: 10782908
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (1 g-0.2 g every 8 h intravenously, then 500 mg-125 mg every 8 h orally)
Study: 10782908
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g every 6 h intravenously)
Study: 10782908
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (for patients on prophylactic norfloxacin)
Study: 768913
Drug: Acebutolol (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (600 mg/day)
Study: 2870124
Drug: Metoprolol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (300 mg/day)
Study: 20199265
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment of femoropopliteal arteries
Study: 11982840
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine (10 microg x kg(‐1)) with 0.5% tetracaine D10 (hyperbaric morphine group)
Study: 11982840
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine mixed with saline after 0.5% tetracaine D10 (hypobaric morphine group)
Study: 16490430
Drug: Rosiglitazone monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone monotherapy at 4 mg/day for 3 months
Study: 16490430
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rosiglitazone at 4 mg/day and atorvastatin at 10 mg/day for 3 months
Study: 12969088
Drug: L30AC (twice‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: L30AC (twice‐daily 30 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days)
Study: 12969088
Drug: L15AC (twice‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: L15AC (twice‐daily 15 mg lansoprazole, 1000 mg amoxicillin and 500 mg clarithromycin for 7 days)
Study: 12969088
Drug: LP (once‐daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: LP (once‐daily 15 mg lansoprazole for 14 days)
Study: 11038044
Drug: LV5FU2 regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 regimen (leucovorin 100 mg/m2 + 5-FU 400 mg/m2 bolus + 5-FU 600 mg/m2 infusion)
Study: 11038044
Drug: LV5FU2 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 + CPT-11 regimen (CPT-11 at 180 mg/m2 on day 1 before LV5FU2)
Study: 3888594
Drug: Intravenous cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cimetidine and pirenzepine (group A)
Study: 3888594
Drug: Intragastric magnesium-aluminium-hydroxide
Normalized name: aluminium hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intragastric magnesium-aluminium-hydroxide concentrate (antacid, group B)
Study: 24997616
Drug: Steroid +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid + bupivacaine
Study: 22992072
Drug: BG-12 (twice-daily,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (twice-daily, 240 mg)
Study: 22992072
Drug: BG-12 (thrice-daily,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (thrice-daily, 240 mg)
Study: 22992072
Drug: BG-12 (twice-daily)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (twice-daily)
Study: 22992072
Drug: BG-12 (thrice-daily)
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG-12 (thrice-daily)
Study: 20808333
Drug: Phytosterol-abundant diet
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-abundant diet (449 mg phytosterols/2000 kcal)
Study: 20808333
Drug: Phytosterol-poor diet
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol-poor diet (126 mg phytosterols/2000 kcal)
Study: 9925124
Drug: Fructooligosaccharides (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructooligosaccharides (15 g/d)
Study: 9925124
Drug: Glucose as
Normalized name: Publix Glucose Assorted Flavors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose as a placebo (4 g/d)
Study: 7768081
Drug: Combined lipo-PGE1/glucagon-insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined lipo-PGE1/glucagon-insulin therapy (group B)
Study: 7768081
Drug: Glucagon-insulin therapy
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon-insulin therapy only (group A)
Study: 6998537
Drug: Prophylactic co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic co-trimoxazole (single dose)
Study: 31112457
Drug: 10 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 session psychiatric standard treatment with added Plan Analysis and Motive Oriented Therapeutic Relationship
Study: 31112457
Drug: 10 session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 session psychiatric standard treatment without the added Plan Analysis and Motive Oriented Therapeutic Relationship
Study: 22948339
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy
Study: 17900321
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of a multispecies probiotic, Ecologic AAD (10(9) cfu/g), twice daily for 14 days
Study: 16231754
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of morning home blood pressure in patients taking antihypertensive drugs
Study: 10088180
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no calcitriol treatment)
Study: 8527710
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 600 mg orally per day for 6 months
Study: 7190412
Drug: Clofibate and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofibate and biguanide treatment
Study: 30115068
Drug: Plant extract
Normalized name: Plant extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant extract based supplement
Study: 26831610
Drug: Telmisartan 40/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40/80 mg once daily with lifestyle modification (TL)
Study: 26831610
Drug: Lifestyle modification
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle modification (L)
Study: 23362618
Drug: Low-dose MF59-adjuvanted
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MF59-adjuvanted A/H5N1 vaccine (3.75 μg)
Study: 23362618
Drug: Licensed higher-dose
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Licensed higher-dose A/H5N1 vaccine (7.5 mg)
Study: 23362618
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (low-dose and licensed)
Study: 19573142
Drug: Specific Oral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific Oral Tolerance Induction (SOTI)
Study: 16834647
Drug: Periprostatic lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Periprostatic lidocaine injection (5 mL of 2% lidocaine solution injected near the junction of the seminal vesicle with the base of the prostate)
Study: 16834647
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel (20 mL of 2% lidocaine gel intrarectally)
Study: 16834647
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline injection (5 mL normal saline injected along the neurovascular bundles)
Study: 10574640
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg chlormadinone acetate
Study: 8623152
Drug: Cyclosporine emulsion
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine emulsion capsules
Study: 8623152
Drug: Cyclosporine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (oral solution for microemulsion)
Study: 1778088
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac dispersible 3-times daily for 4 weeks
Study: 1778088
Drug: Placebo 3-times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3-times daily for 4 weeks
Study: 1778088
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg diclofenac dispersible
Study: 29523524
Drug: Chlorthalidone (thiazide-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (thiazide-like diuretic)
Study: 25832522
Drug: Heroin-assisted treatment
Normalized name: heroin
DrugBank: Diamorphine (DB01452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin-assisted treatment (HAT) for 12 months
Study: 25832522
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance treatment (Control)
Study: 23524942
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2 on days 1 and 2) and capecitabine (750 mg/m2 in two divided doses from day 1-14)
Study: 23524942
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2 on days 1 and 2) and 5-FU (750 mg/m2 on days 1, 2, and 3)
Study: 19671877
Drug: ipilimumab with
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab with daily blinded budesonide (group A)
Study: 9466064
Drug: Neomycin/dexamethasone spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin/dexamethasone spray (Otomize)
Study: 8192128
Drug: Treatment attendance
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment attendance
Study: 25602857
Drug: Exercise-based cardiac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-based cardiac rehabilitation (ECR) consisting of 8 weeks of aerobic exercise at 70-85% of maximal heart rate during 3 sessions weekly plus usual care
Study: 23777763
Drug: post‐rVWF‐rFVIII infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: post‐rVWF‐rFVIII infusion
Study: 8996345
Drug: 200 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 micrograms desmopressin tablets
Study: 8996345
Drug: 400 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 micrograms desmopressin tablets
Study: 8996345
Drug: 20 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 micrograms nasal spray
Study: 8996345
Drug: Desmopressin tablets
Normalized name: desmopressin Sublingual Tablet
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Desmopressin tablets (both doses)
Study: 8424470
Drug: Nortriptyline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline (100 mg median nightly dose for 6 weeks)
Study: 3307548
Drug: Propanidid (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propanidid (9 mg X kg‐1 IVD, and 60 mg X kg‐1 X h‐1)
Study: 3307548
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg X kg‐1 IVD, and 9 mg X kg‐1 X h‐1)
Study: 29466550
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (Van Riper, 1939)
Study: 22562977
Drug: adalimumab therapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: adalimumab therapy
Study: 20581215
Drug: Pregabalin 50
Normalized name: pregabalin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 50 mg, Pregabalin 75 mg, Placebo
Study: 15935272
Drug: Metal-free polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metal-free polymer crowns with chamfer finishing line or shoulder preparation
Study: 11826695
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 2% xylocaine with 1:80,000 epinephrine
Study: 9893655
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy (FEC: 5‐fluorouracil 600 mg/m2, epidoxorubicin 60 mg/m2, cyclophosphamide 600 mg/m2)
Study: 9893655
Drug: Pathological complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathological complete response after induction treatment
Study: 9893655
Drug: Low [3H]‐dT‐LI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low [3H]‐dT‐LI after primary chemotherapy
Study: 9893655
Drug: Bcl-2 expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bcl-2 expression before primary chemotherapy
Study: 9893655
Drug: Bcl-2 expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bcl-2 expression after primary chemotherapy
Study: 3277083
Drug: Clonazepam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam (0.25 to 0.5 mg/d)
Study: 23097067
Drug: Sildenafil (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (target dose 40 mg three times per day)
Study: 10757621
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (50 pmol/kg x h)
Study: 8818093
Drug: Tea (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea (150 ml)
Study: 8818093
Drug: Apple juice
Normalized name: apple juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apple juice (150 ml)
Study: 1446762
Drug: Hyaluronidase (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronidase (50 i.u./ml) and adrenaline (1:200,000)
Study: 27351245
Drug: Curcumin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (500 mg/day)
Study: 25881813
Drug: Routine methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine methods plus dietary sweet potato consumption (200 g/d from admission to discharge)
Study: 17383174
Drug: Topical vitamin
Normalized name: vitamin A Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vitamin E (800 mg)
Study: 7852539
Drug: Benfluorex (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benfluorex (150 mg) three times daily for 6 weeks
Study: 26712981
Drug: IV clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV clonidine 4 µg/kg
Study: 26712981
Drug: IV clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV clonidine 5 µg/kg
Study: 26712981
Drug: IV clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV clonidine 3 µg/kg
Study: 22338149
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rituximab weekly for 4 weeks (group A)
Study: 22338149
Drug: 375 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg/m2 rituximab single dose (group B)